1100318-96-4

Basic information

• Product Name: 7H-Pyrrolo[2,3-d]pyriMidine, 4-iodo-
• Synonyms: 7H-Pyrrolo[2,3-d]pyriMidine, 4-iodo-;4-Iodo-7H-pyrrolo[2,3-d]pyrimidine
• CAS NO: 1100318-96-4
• Molecular Formula: C₆H₄IN₃
• Molecular Weight: 245.02053
• EINECS: -0
• Mol File: 1100318-96-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 2.219±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 11.28±0.50(Predicted)
• CAS DataBase Reference: 7H-Pyrrolo[2,3-d]pyriMidine, 4-iodo-(CAS DataBase Reference)
• NIST Chemistry Reference: 7H-Pyrrolo[2,3-d]pyriMidine, 4-iodo-(1100318-96-4)
• EPA Substance Registry System: 7H-Pyrrolo[2,3-d]pyriMidine, 4-iodo-(1100318-96-4)

Safety Data

• Hazardous Substances Data: 1100318-96-4(Hazardous Substances Data)

Usage

General Description

7H-Pyrrolo[2,3-d]pyrimidine, 4-iodo-, also known as 4-iodo-7H-pyrrolo[2,3-d]pyrimidine, is a synthetic chemical compound belonging to the class of organic compounds known as pyrrolopyrimidines. Pyrrolopyrimidines are compounds containing a pyrrolopyrimidine moiety, which consists of a pyrrole ring fused to a pyrimidine ring. 4-Iodo-7H-pyrrolo[2,3-d]pyrimidine carries an iodine atom at the 4-position. The exact properties of this chemical, including its molecular weight, volatility, solubility, and potential uses, can vary depending on its specific structure and any additional chemical group it may carry. Its biological impact and toxicity are not typically well-known and would require further review and investigation to establish.

Upstream product

• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 1100318-38-4 4-chloro-N-[5-chloro-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)-phenyl]-3-trifluoromethyl-benzenesulfonamide 
• 1100318-49-7 4-methyl-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)-pyridin-3-yl]-3-trifluoromethyl-benzenesulfonamide 

Relevant articles and documents

The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3

Members of the Janus kinase (JAK) family are potential therapeutic targets. Abnormal signaling by mutant JAK2 is related to hematological malignancy, such as myeloproliferative neoplasms (MPNs), and tyrosine kinase inhibitor (TKI)-resistance in non-small cell lung cancer (NSCLC). We discovered a potent and highly selective inhibitor of JAK2 over JAK1 and -3 based on the structure of 4-(2,5-triazole)-pyrrolopyrimidine. Among all triazole compounds tested, 2,5-triazole regioisomers more effectively inhibited JAK2 kinase activity than isomers with substitutions of various alkyl groups at the R2position, except for methyl-substituted 1,5-triazole, which was more potent than the corresponding 1,4- and 2,5-triazoles. None of the synthesized 1,4-isomers inhibited all three JAK family members. Compounds with phenyl or tolyl group substituents at the R1position were completely inactive compared with the corresponding analogues with a methyl substituted at the R1position. As a result of this structure–activity relationship, 54, which is substituted with a cyclopropylmethyl moiety, exhibited significant inhibitory activity and selectivity (IC50= 41.9 nM, fold selectivity JAK1/2 10.6 and JAK3/2 58.1). Compound 54 also exhibited an equivalent inhibition of wild type JAK2 and the V617F mutant. Moreover, 54 inhibited the proliferation of HEL 92.1.7 cells, which carry JAK2 V617F, and gefitinib-resistant HCC827 cells. Compound 54 also suppressed STAT3 phosphorylation at Y705.

Substituted 7H-pyrrolo[2,3-d]pyrimidine derivative and preparation method and application thereof

The invention provides a substituted 7H-pyrrolo[2,3-d]pyrimidine derivative and a preparation method and application thereof, and specifically provides a compound as shown in a formula I, or pharmaceutically-acceptable salts thereof, or a racemate thereof

Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition

A solution-phase parallel synthesis of triazole-derived ruxolitinib analogues was developed in the current study. The method employs copper-catalyzed azide-alkyne cycloaddition to build up the central triazole template. Product isolation by precipitation